[{"id":"29889af3-ae43-4e06-bdfc-acec22c139fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT07198867","created_at":"2025-10-04T08:02:56.736Z","updated_at":"2025-10-04T08:02:56.736Z","phase":"Phase 1","brief_title":"A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT07198867","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-09-30"},{"id":"1788e76b-7d7b-4891-bdd0-dfbb58176132","acronym":"","url":"https://clinicaltrials.gov/study/NCT07046078","created_at":"2025-07-05T13:57:24.531Z","updated_at":"2025-07-05T13:57:24.531Z","phase":"Phase 2","brief_title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","source_id_and_acronym":"NCT07046078","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • fludarabine IV • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2025-07-02"},{"id":"9fd3bca0-1c10-442b-a00f-722b814378c6","acronym":"CD33 CAR NK","url":"https://clinicaltrials.gov/study/NCT07026942","created_at":"2025-06-21T13:17:33.882Z","updated_at":"2025-06-21T13:17:33.882Z","phase":"Phase 1/2","brief_title":"Phase I/II Clinical Trial Evaluating the Safety and Efficacy of Universal Donor CD33 CAR Natural Killer Cells for Treatment of Myeloid Leukemia","source_id_and_acronym":"NCT07026942 - CD33 CAR NK","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2031","primary_completion_date":" 07/01/2031","study_txt":" Completion: 07/01/2037","study_completion_date":" 07/01/2037","last_update_posted":"2025-06-18"},{"id":"611d069e-ba56-4015-ba56-94bebd608133","acronym":"","url":"https://clinicaltrials.gov/study/NCT03839446","created_at":"2021-01-18T18:57:17.044Z","updated_at":"2025-02-25T13:52:47.649Z","phase":"Phase 2","brief_title":"Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy","source_id_and_acronym":"NCT03839446","lead_sponsor":"Robert Redner, MD","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 02/02/2023","primary_completion_date":" 02/02/2023","study_txt":" Completion: 12/22/2024","study_completion_date":" 12/22/2024","last_update_posted":"2025-02-20"},{"id":"6280dfa5-ede9-4d89-a587-10249cd79abf","acronym":"AGORA-1","url":"https://clinicaltrials.gov/study/NCT05199051","created_at":"2022-01-20T15:53:56.079Z","updated_at":"2025-02-25T14:02:40.845Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML","source_id_and_acronym":"NCT05199051 - AGORA-1","lead_sponsor":"Centre Antoine Lacassagne","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/03/2023","start_date":" 06/03/2023","primary_txt":" Primary completion: 03/15/2027","primary_completion_date":" 03/15/2027","study_txt":" Completion: 03/15/2027","study_completion_date":" 03/15/2027","last_update_posted":"2025-02-19"},{"id":"5a8a1ba9-7750-4d42-886f-26c4d198762e","acronym":"NCI-2018-01812","url":"https://clinicaltrials.gov/study/NCT03672539","created_at":"2021-01-18T18:00:52.647Z","updated_at":"2025-02-25T15:43:12.491Z","phase":"Phase 2","brief_title":"Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03672539 - NCI-2018-01812","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/07/2018","start_date":" 11/07/2018","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-10"},{"id":"5adabdf3-1484-4c8e-ac66-a9230e113fb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04915612","created_at":"2021-06-07T15:53:27.598Z","updated_at":"2025-02-25T15:35:05.555Z","phase":"Phase 1","brief_title":"Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04915612","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 05/21/2021","start_date":" 05/21/2021","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-10"},{"id":"610f01eb-c68e-44f8-9b23-e46ae4e5528c","acronym":"GO-TAG","url":"https://clinicaltrials.gov/study/NCT05716009","created_at":"2023-02-08T18:00:15.099Z","updated_at":"2025-02-25T15:27:53.038Z","phase":"Phase 1","brief_title":"Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML","source_id_and_acronym":"NCT05716009 - GO-TAG","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD33 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["CD33 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 12/25/2027","primary_completion_date":" 12/25/2027","study_txt":" Completion: 12/25/2028","study_completion_date":" 12/25/2028","last_update_posted":"2025-02-10"},{"id":"67917d6a-e1b0-409b-853a-7e9fd258dd6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06802523","created_at":"2025-02-25T16:34:56.075Z","updated_at":"2025-02-25T16:34:56.075Z","phase":"Phase 1","brief_title":"Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT06802523","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine) • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-07"},{"id":"d48274bb-de2d-4319-b258-4def71b8a13e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05558124","created_at":"2022-09-28T14:56:07.027Z","updated_at":"2025-02-25T16:33:08.602Z","phase":"Phase 1","brief_title":"CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML","source_id_and_acronym":"NCT05558124","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/16/2023","start_date":" 02/16/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-07"},{"id":"2bca17a4-1b77-4b70-bb2a-a5dcd7c531ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672147","created_at":"2023-01-05T14:58:28.476Z","updated_at":"2025-02-25T16:39:33.579Z","phase":"Phase 1","brief_title":"CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05672147","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-CD33 CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 12/07/2023","start_date":" 12/07/2023","primary_txt":" Primary completion: 09/03/2028","primary_completion_date":" 09/03/2028","study_txt":" Completion: 09/03/2028","study_completion_date":" 09/03/2028","last_update_posted":"2025-02-06"},{"id":"3e6558d8-f022-4465-b340-329db64b8a39","acronym":"VBP101","url":"https://clinicaltrials.gov/study/NCT04849910","created_at":"2021-04-19T11:53:06.069Z","updated_at":"2025-02-25T17:01:02.310Z","phase":"Phase 1/2","brief_title":"Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment with Mylotarg, for Patients with CD33+ AML or MDS","source_id_and_acronym":"NCT04849910 - VBP101","lead_sponsor":"Vor Biopharma","biomarkers":" CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" CD33 expression","tags":["CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • tremtelectogene empogeditemcel (VOR33)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-03"},{"id":"6e878a86-14bd-474e-806a-2260460e86af","acronym":"VBP301","url":"https://clinicaltrials.gov/study/NCT05984199","created_at":"2023-08-09T14:09:38.757Z","updated_at":"2025-02-25T17:02:46.628Z","phase":"Phase 1/2","brief_title":"Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant","source_id_and_acronym":"NCT05984199 - VBP301","lead_sponsor":"Vor Biopharma","biomarkers":" CD33 • HLA-DRB1","pipe":"","alterations":" ","tags":["CD33 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VCAR33ALLO"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-02-03"},{"id":"d2f2a1f1-7bb1-4919-a610-7815b806ac30","acronym":"NCI-2019-01726","url":"https://clinicaltrials.gov/study/NCT03900949","created_at":"2021-01-18T19:12:29.931Z","updated_at":"2024-07-02T16:35:01.958Z","phase":"Phase 1","brief_title":"Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT03900949 - NCI-2019-01726","lead_sponsor":"Uma Borate","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" CD33 positive • CD33 expression","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive • CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Suspended","enrollment":" Enrollment 18","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-22"},{"id":"88461e0e-9239-461f-831e-38bf1a8c7c20","acronym":"","url":"https://clinicaltrials.gov/study/NCT04207190","created_at":"2021-01-18T20:29:32.215Z","updated_at":"2024-07-02T16:35:05.019Z","phase":"Phase 1","brief_title":"Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04207190","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-08"},{"id":"59506a1f-78d0-44c7-9ec4-22c51f22d853","acronym":"","url":"https://clinicaltrials.gov/study/NCT04050280","created_at":"2021-01-18T19:51:44.499Z","updated_at":"2024-07-02T16:35:11.259Z","phase":"Phase 2","brief_title":"CLAG-GO for Patients With Persistent, Relapsed or Refractory AML","source_id_and_acronym":"NCT04050280","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Mylotarg (gemtuzumab ozogamicin) • cladribine"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-04-05"},{"id":"65b8b469-ba1f-453c-992d-ec880c54605c","acronym":"NCI-2018-01613","url":"https://clinicaltrials.gov/study/NCT03737955","created_at":"2021-01-18T18:18:29.778Z","updated_at":"2024-07-02T16:35:12.661Z","phase":"Phase 2","brief_title":"Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03737955 - NCI-2018-01613","lead_sponsor":"University of Washington","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 11/30/2018","start_date":" 11/30/2018","primary_txt":" Primary completion: 03/15/2023","primary_completion_date":" 03/15/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-27"},{"id":"bdb1c58a-74c6-4750-9dd9-d9830096d0d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03291444","created_at":"2021-01-18T16:15:39.130Z","updated_at":"2024-07-02T16:35:14.542Z","phase":"Phase 1","brief_title":"CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS","source_id_and_acronym":"NCT03291444","lead_sponsor":"Zhujiang Hospital","biomarkers":" KIT • CD20 • IL6 • CD38 • WT1 • CD22 • CD33 • CD34 • NCAM1 • MME • IL3RA","pipe":" | ","alterations":" CD20 positive","tags":["KIT • CD20 • IL6 • CD38 • WT1 • CD22 • CD33 • CD34 • NCAM1 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/05/2018","start_date":" 05/05/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-15"},{"id":"1debacb5-f874-42c5-94ad-4212182706f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04980404","created_at":"2021-07-28T19:52:31.805Z","updated_at":"2024-07-02T16:35:15.753Z","phase":"Phase 1","brief_title":"Inqovi Maintenance Therapy in Myeloid Neoplasms","source_id_and_acronym":"NCT04980404","lead_sponsor":"Massachusetts General Hospital","biomarkers":" CD33 • HLA-B","pipe":" | ","alterations":" CD33 expression","tags":["CD33 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/17/2021","start_date":" 09/17/2021","primary_txt":" Primary completion: 08/24/2023","primary_completion_date":" 08/24/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-03-08"},{"id":"953bda82-1253-4a08-bd57-a04465e99aa4","acronym":"PLAT-08","url":"https://clinicaltrials.gov/study/NCT05105152","created_at":"2021-11-03T12:53:01.635Z","updated_at":"2024-07-02T16:35:16.603Z","phase":"Phase 1","brief_title":"PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML","source_id_and_acronym":"NCT05105152 - PLAT-08","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • DARIC33"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 01/31/2041","study_completion_date":" 01/31/2041","last_update_posted":"2024-03-04"},{"id":"7e5df265-735a-4b50-970f-ba82acf13b08","acronym":"","url":"https://clinicaltrials.gov/study/NCT05189639","created_at":"2022-01-12T14:53:46.362Z","updated_at":"2024-07-02T16:35:19.384Z","phase":"","brief_title":"A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia","source_id_and_acronym":"NCT05189639","lead_sponsor":"Pfizer","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 12/05/2023","start_date":" 12/05/2023","primary_txt":" Primary completion: 11/17/2027","primary_completion_date":" 11/17/2027","study_txt":" Completion: 11/17/2027","study_completion_date":" 11/17/2027","last_update_posted":"2024-02-14"},{"id":"e55830f0-b06e-4c54-bab4-91b6f117fa14","acronym":"","url":"https://clinicaltrials.gov/study/NCT04582487","created_at":"2021-01-18T21:51:58.830Z","updated_at":"2024-07-02T16:35:20.351Z","phase":"","brief_title":"Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL","source_id_and_acronym":"NCT04582487","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" KIT • CD8 • CD33 • CD34 • CD5 • ITGAM • ANPEP","pipe":"","alterations":" ","tags":["KIT • CD8 • CD33 • CD34 • CD5 • ITGAM • ANPEP"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-02-07"},{"id":"417e8b04-49ba-41fb-98db-3a2a6390d025","acronym":"","url":"https://clinicaltrials.gov/study/NCT04070768","created_at":"2021-01-18T19:55:46.986Z","updated_at":"2024-07-02T16:35:26.408Z","phase":"Phase 1","brief_title":"Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113","source_id_and_acronym":"NCT04070768","lead_sponsor":"John Quigley","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" CD33 expression","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/06/2019","start_date":" 09/06/2019","primary_txt":" Primary completion: 10/12/2023","primary_completion_date":" 10/12/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-12-13"},{"id":"35641ab2-6f4d-40e3-8334-a2f46e81a6fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05020912","created_at":"2021-08-25T14:53:19.986Z","updated_at":"2024-07-02T16:35:29.739Z","phase":"Phase 2","brief_title":"Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy","source_id_and_acronym":"NCT05020912","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" PD-L1 • CD8 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD33 • TIGIT • CD4 • IL7R • NCAM1 • S100A9 • FOXP3","pipe":" | ","alterations":" LAG3 expression","tags":["PD-L1 • CD8 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD33 • TIGIT • CD4 • IL7R • NCAM1 • S100A9 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-11-09"}]